Clinical Perspectives on the Treatment of Neuroendocrine Tumors

Daneng Li, MD; Lowell B. Anthony, MD, FACP; Christopher Lieu, MD; and Chandrikha Chandrasekharan, MBBS, discuss how the treatment landscape for neuroendocrine tumors has evolved significantly over the past few decades with the introduction of multiple therapeutic options including somatostatin analogs, targeted therapies like everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), and the recent approval of cabozantinib, which provides new sequencing opportunities and fills treatment gaps for heavily pretreated patients while emphasizing the importance of individualized patient care and shared decision-making in this complex disease.